CellCept, Mycophenolate
CellCept, Mycophenolate Newswire

CellCept, Mycophenolate Newswire

Comprehensive Real-Time News Feed for CellCept, Mycophenolate (generic).

Results 1 - 20 of 37 in CellCept, Mycophenolate (generic)

  1. Steroid-refractory chronic GVHD trial results 'overestimate' treatment efficacyRead the original story w/Photo

    Friday Jul 24 | Medical News

    Trial results for patients with steroid-refractory chronic graft versus host have overestimated the efficacies of treatments, suggests a meta-analysis published in The Lancet Haematology . However, the authors believe that future trials could reduce this bias by following a 61-point checklist of guidelines, based on the US National Institute of Health consensus project on SR-cGVHD in 2006.

    Comment?

  2. AAV1.NT-3 gene therapy attenuates spontaneous autoimmune peripheral polyneuropathyRead the original story

    Thursday Jul 23 | Gene Therapy

    Correspondence: Dr Z Sahenk, Center for Gene Therapy, The Research Institute at Nationwide Children’s Hospital, 700 Children’s Drive, Room WA3011, Columbus, OH 43205, USA. E-mail: Zarife.Sahenk@nationwidechildrens.org Received 5 March 2015; Revised 20 May 2015; Accepted 4 June 2015 Accepted article preview online 30 June 2015; Advance online publication 23 July 2015 The spontaneous autoimmune peripheral polyneuropathy model in B7-2 knockout non-obese diabetic mice shares clinical and histological features with chronic inflammatory demyelinating polyradiculoneuropathy .

    Comment?

  3. Efficacy of galactose and adalimumab in patients with resistant...Read the original story

    Wednesday Jul 22 | BioMed Central

    This is an Open Access article distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver applies to the data made available in this article, unless otherwise stated.

    Comment?

  4. Acute Orthotopic Heart Transplantation Rejection With ST-Segment...Read the original story

    Tuesday Jul 21 | Circulation

    From the Division of Cardiology , Department of Medicine , Montefiore Medical Center, Bronx, NY. Correspondence to Peter Vlismas, MD, Montefiore Medical Center, 111 E 210 St, N W 3 Room 351, Bronx, NY 10467.

    Comment?

  5. Preclinical report on allogeneic uterus transplantation in non-human primates.Read the original story

    Monday Jul 13 | CiteULike

    Is it possible to perform allogeneic uterus transplantation with a donation from a live donor in a non-human primate species and what immunosuppression is needed to prevent rejection? Allogeneic UTx in the baboon is a donor- and recipient-safe surgical procedure; immunosuppression with induction therapy and a triple protocol should be used. UTx may become a treatment for absolute uterine factor infertility.

    Comment?

  6. Recent advances in autoimmune pancreatitisRead the original story

    Sunday Jun 28 | GastroHep.com

    Autoimmune pancreatitis is a form of chronic pancreatitis that is characterized clinically by frequent presentation with obstructive jaundice, histologically by a dense lymphoplasmacytic infiltrate with fibrosis, and therapeutically by a dramatic response to corticosteroid therapy. Dr Suresh Chan and colleagues from Minnesota, USA investigate the 2 disease types as well as recent advances in autoimmune pancreatiisis.

    Comment?

  7. mycophenolate mofetilRead the original story w/Photo

    Jun 2, 2015 | MedicineNet

    Jay W. Marks, MD, is a board-certified internist and gastroenterologist. He graduated from Yale University School of Medicine and trained in internal medicine and gastroenterology at UCLA/Cedars-Sinai Medical Center in Los Angeles.

    Comment?

  8. Donald Hricik, MD, Receives AST Lifetime Achievement AwardRead the original story

    May 18, 2015 | PRWeb

    The American Society of Transplantation awarded its highest honor, the Lifetime Achievement Award, to Donald Hricik, MD, at the recent American Transplant Congress. Dr. Hricik has moved the field forward through both his involvement in clinical trials that have shaped our care of transplant patients and through his education of the next generation of transplant professionals.

    Comment?

  9. Everolimus-based, calcineurin-inhibitor-free regimen in recipients of ...Read the original story

    Apr 22, 2015 | CiteULike

    Non-nephrotoxic immunosuppressive strategies that allow reduction of calcineurin-inhibitor exposure without compromising safety or efficacy remain a goal in kidney transplantation. Immunosuppression based on the mammalian-target-of-rapamycin inhibitor everolimus was assessed as a strategy for elimination of calcineurin-inhibitor exposure and optimisation of renal-graft function while maintaining efficacy.

    Comment?

  10. Treatment of progressive IgA nephropathy: an update.Read the original story

    Apr 18, 2015 | CiteULike

    To insert individual citation into a bibliography in a word-processor, select your preferred citation style below and drag-and-drop it into the document. IgA nephropathy is the most common primary glomerular disease worldwide.

    Comment?

  11. Is newer safer? Adverse events associated with first-line therapies...Read the original story

    Apr 15, 2015 | CiteULike

    Clinical outcomes in ANCA-associated vasculitis and lupus nephritis have improved greatly with treatment regimens containing high-dose glucocorticoids and cyclophosphamide. However, with the use of these medications come significant adverse events, most notably infections, cytopenias, malignancies, and reproductive abnormalities.

    Comment?

  12. Rituximab as Induction Therapy After Renal Transplantation: A...Read the original story

    Apr 15, 2015 | CiteULike

    To insert individual citation into a bibliography in a word-processor, select your preferred citation style below and drag-and-drop it into the document. We evaluated the efficacy and safety of rituximab as induction therapy in renal transplant patients.

    Comment?

  13. Aurinia Reports Fourth Quarter And Full Year 2014 Financial Results...Read the original story

    Mar 30, 2015 | BioSpace

    Aurinia Pharmaceuticals Inc. has released its financial results for the fourth quarter and year ended December 31, 2014. Amounts, unless specified otherwise, are expressed in U.S. dollars.

    Comment?

  14. Evaluating the efficacy, safety and evolution of renal function with ...Read the original story

    Mar 25, 2015 | Trials Journal

    Background Introduction of calcineurin inhibitors had led to improved survival rates in liver transplant recipients. However, long-term use of calcineurin inhibitors is associated with a higher risk of chronic renal failure, neurotoxicity, de novo malignancies, recurrence of hepatitis C viral infection and hepatocellular carcinoma.

    Comment?

  15. Glory Biotech Co., Ltd. (4187) - Financial and Strategic SWOT...Read the original story

    Mar 24, 2015 | PR-inside.com

    Glory Biotech Co., Ltd. is a biopharmaceutical company. The company develops and produces active pharmaceutical ingredients and healthcare foods from microorganism.

    Comment?

  16. Which dose of steroids and which cytotoxics for severe lupus?Read the original story

    Mar 24, 2015 | CiteULike

    To insert individual citation into a bibliography in a word-processor, select your preferred citation style below and drag-and-drop it into the document. There have been a number of major advances in the treatment of systemic lupus erythematosus and we are now in the era of biologic therapies for this multisystem autoimmune disorder.

    Comment?

  17. Maintenance therapy in antineutrophil cytoplasmic antibody-associated ...Read the original story

    Mar 23, 2015 | CiteULike

    Anti-neutrophil cytoplasmic autoantibody -associated vasculitides are severe chronic auto-immune diseases in which the small vessels are inflamed. Nowadays, in the majority of patients disease can be brought into remission with cyclophosphamide and corticosteroids.

    Comment?

  18. Comparison of non-myeloablative conditioning regimens for lymphoproliferative disordersRead the original story

    Mar 4, 2015 | Bone Marrow Transplantation

    Correspondence: Dr MC Pasquini, Center for International Blood and Marrow Transplant Research, Department of Medicine, Medical College of Wisconsin, 9200 West Wisconsin Avenue, Suite C5500, Milwaukee, WI 53226, USA. E-mail: mpasquini@mcw.edu Hematopoietic cell transplantation with non-myeloablative conditioning for lymphoproliferative diseases includes fludarabine with and without low-dose TBI.

    Comment?

  19. Successful treatment of refractory childhood pemphgus vulgaris with...Read the original story

    Feb 21, 2015 | CiteULike

    Pediatric dermatology , Vol. 22, No. 5. , pp. 461-464, doi:10.1111/j.1525-1470.2005.00118.x To insert individual citation into a bibliography in a word-processor, select your preferred citation style below and drag-and-drop it into the document.

    Comment?

  20. Aurinia To Initiate An Open Label Clinical Study To Investigate The...Read the original story

    Feb 8, 2015 | BioSpace

    Aurinia Pharmaceuticals Inc. today announced that it will initiate an open label, exploratory study to assess the short term predictors of response using voclosporin in combination with mycophenolate mofetil in patients with active lupus nephritis. AURION will examine biomarkers of disease activity at 8 weeks and their ability to predict response at 24 and 48 weeks.

    Comment?